Dasatinib + Quercetin
D+Q senolytic combination
Dasatinib + Quercetin (D+Q senolytic combination) is a longevity & bioregulators research compound. Dasatinib is a tyrosine kinase inhibitor and quercetin a flavonoid; together they push senescent cells past the apoptotic threshold those cells normally resist. Because senescent cells are cleared and don't return immediately, the dosing is intermittent rather than continuous — a genuinely different pharmacological model.
Dasatinib + Quercetin quick facts
| Reported research dose | Dasatinib 100mg + Quercetin 1000mg x3 days |
| Route | Oral |
| Frequency | Not established — no dosing protocol has been characterized |
| Half-life | Dasatinib ~3-5 hrs |
| Forms | Oral |
| Evidence level | Early human pilot trials; strong rodent data |
The most-studied senolytic pairing, and still early. Small human pilots in idiopathic pulmonary fibrosis and diabetic kidney disease showed reduced senescent cell burden. Dasatinib is a chemotherapy agent with a real toxicity profile — myelosuppression, pleural effusion, bleeding risk, QT effects — and the quercetin half is the only part you can buy. Taking quercetin alone is not a senolytic protocol. Prescription, oncology-grade drug.
How Dasatinib + Quercetin works
Dasatinib is a tyrosine kinase inhibitor and quercetin a flavonoid; together they push senescent cells past the apoptotic threshold those cells normally resist. Because senescent cells are cleared and don't return immediately, the dosing is intermittent rather than continuous — a genuinely different pharmacological model.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Can you actually get Dasatinib + Quercetin?
Dasatinib is a leukemia chemotherapy drug. The senolytic protocol is a research setting, not a purchase — and I won't link a route to it.
The evidence for Dasatinib + Quercetin
Graded by what exists behind each claim.
✅ Clinically validated
- Small human pilot trials exist and they are genuinely first-in-class. An open-label pilot in idiopathic pulmonary fibrosis (14 patients) reported improved physical function, and a pilot in diabetic kidney disease reported a measurable reduction in senescent cell burden in adipose tissue and skin after three days of dosing.
- These are tiny, uncontrolled, and short. They establish that senolysis can be measured in humans — which is a real milestone — not that it produces clinical benefit. Larger randomized trials are running.
📊 Correlative data
- Community use follows the trial protocol: intermittent 'hit and run' dosing for two to three days every few weeks, rather than continuously. The intermittent schedule is mechanistically motivated — you only need to be present long enough to kill cells that are already senescent.
- Dasatinib is a prescription chemotherapy agent with real toxicity — myelosuppression, pleural effusion, bleeding risk and QT effects — and its record comes from leukemia patients, not healthy adults.
🧪 Theoretical / extrapolated
- Senescent cells stop dividing but do not die, and secrete an inflammatory mix (the SASP) that damages surrounding tissue. They accumulate with age, and clearing them extends healthspan in mice.
- The pair is complementary by design: senescent cells resist apoptosis through several different survival pathways, and no single agent covers them all. Dasatinib inhibits tyrosine kinase-dependent survival signaling, quercetin hits BCL-2 family and PI3K pathways. Different cell types depend on different ones.
- The mechanism predicts a specific risk: forcing apoptosis in a large cell population releases debris and inflammatory contents, and in someone with a heavy senescent burden that clearance load falls on the liver and kidneys.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Dasatinib + Quercetin actually does
The pairing is not a designed combination. It is the answer to an experiment, and knowing that changes how you read every claim about it. Zhu 2015 asked why senescent cells do not die. A senescent cell is damaged enough that apoptosis should have removed it and it persists anyway, secreting inflammatory mediators. The paper's answer — its own title calls it the Achilles' heel — is that these cells survive by upregulating anti-apoptotic networks, and that different senescent cell types lean on different networks.
That is why there are two drugs and not one. Zhu 2015 found dasatinib effective against senescent human preadipocytes, which depend on ephrin-dependent tyrosine kinase signaling, and quercetin effective against senescent endothelial cells, which lean on a different survival network. Neither alone covered both. The combination exists because senescence is not one cell state with one weakness, and a page that describes D+Q as "a senolytic" has flattened the one finding that explains its design.
Dasatinib is a real drug with a real target list. It is an approved BCR-ABL and SRC-family tyrosine kinase inhibitor used in chronic myeloid leukemia, and it is promiscuous — it hits dozens of kinases, which is why it works here and why it carries the adverse-effect profile it does. Quercetin is a dietary flavonol with a long list of weak activities, of which PI3K/AKT inhibition and BCL-2 family interaction are the relevant ones.
The dosing schedule is a mechanism, not a convenience. Senolytics are given as hit-and-run courses — a few days on, weeks off — and the logic is specific: killing a senescent cell is an event, not a state that needs maintaining, and the population takes weeks to rebuild. Continuous dosing would supply the toxicity of a kinase inhibitor with none of the extra benefit. Wissler Gerdes 2021 works through what that means for trial design, and it is the reason every published protocol is intermittent.
The output is the SASP. What a senescent cell does that matters is secrete — interleukin-6, IL-1, matrix metalloproteinases, chemokines — the senescence-associated secretory phenotype. Clearing the cells is a means; lowering that secretion is the end, and it is the thing a blood test can reach.
Cell, rodent, human — and where it stops
Step one, in cells: the target and the drug choice. Zhu 2015, described above. Cell-type-specific survival networks, and two drugs picked to cover two of them.
Step two, in mice, where the effects are real and sex-dependent. Zhu 2024 reported D+Q protecting against diabetic kidney disease by activating autophagy and relieving podocyte dedifferentiation through the Notch pathway — a named pathway with a named cell type. And Fang 2023 is the study that should be quoted more often: oral D+Q in C57BL/6 mice produced sexually dimorphic metabolic and cognitive responses. The same protocol did different things to male and female animals. Nobody selling this combination stratifies by sex, and the animal data says they should.
Step three, in humans, and the trials are small but they are real. Justice 2019 is the first-in-human study: 14 patients with idiopathic pulmonary fibrosis, open-label, dasatinib 100 mg/day plus quercetin 1250 mg/day, 3 days a week for 3 weeks. Retention was 100%. Physical function improved — 6-minute walk distance, gait speed and chair-stand time, all at p<0.05. Adverse events were common and mostly minor: respiratory symptoms in 16 instances, skin irritation and bruising in 14, gastrointestinal discomfort in 12, with one serious adverse event.
And the mechanistic human result. Zhu 2022 reports that orally active senolytics restore alpha-Klotho in mice and humans. Klotho is a longevity-associated protein that falls with age and with kidney disease. A measurable human biomarker moving in the predicted direction is the strongest translational signal this combination has, and it is far stronger evidence than the anecdotal reports that drive most of the interest.
The obstacles, named one at a time. (1) Fourteen open-label patients with no control arm Justice 2019; a 6-minute walk improves with attention, encouragement and practice. (2) Every published trial is in disease — pulmonary fibrosis, diabetic kidney disease, frailty. Nobody has studied a healthy 45-year-old, which is who buys it. (3) Senescent cells are not uniformly bad: they are required for wound healing and for limiting fibrosis acutely, and clearing them in a healthy person removes a function as well as a burden. (4) The sex difference in Fang 2023 has never been examined in a human study.
What would have to be true, and how you would know it was not
Three predictions. The first two are safety and follow from dasatinib being a real kinase inhibitor; the third is the falsification test.
1. A CBC before and after each course, because dasatinib suppresses marrow. In its licensed oncology use, dasatinib causes neutropenia and thrombocytopenia at the same 100 mg dose the senolytic protocol uses Justice 2019. Intermittent dosing should make that far less likely and has not been shown to make it impossible. A CBC with platelets and neutrophils before a course and 1–2 weeks after is the single most defensible test on this page, and it is the one nobody orders because the compound gets filed under supplements.
2. A CMP and cystatin C, because the drug is cleared hepatically and the target organ in the animal work is the kidney. Dasatinib is a CYP3A4 substrate with a documented hepatic signal, and quercetin at gram doses is not inert either. A CMP covers transaminases and creatinine; cystatin C gives a creatinine-independent filtration estimate, which matters because muscle mass and activity distort creatinine in exactly the population that takes this.
3. The falsification test is hs-CRP, and it may well not move. The mechanism's endpoint is a lower SASP. hs-CRP is the cheapest downstream index of systemic inflammatory tone: draw it at baseline and 4 weeks after a course, in a person with no intercurrent infection. If a person with a normal baseline hs-CRP takes three courses and nothing changes, the honest reading is that there was little senescent burden to clear — which is the most likely situation in a healthy adult, and the reason the trials were run in disease.
What nobody has tested yet
Four experiments nobody has run, and the first is the one that would change practice immediately.
Nobody has run D+Q in healthy middle-aged adults. Every published human study is in disease — pulmonary fibrosis Justice 2019, kidney disease, frailty. The population buying it is healthy and 40 to 60. A placebo-controlled study in that group with alpha-Klotho Zhu 2022 and hs-CRP as endpoints would say whether there is anything to clear, and it has never been proposed.
Nobody has tested whether the sex difference holds in people. Fang 2023 found different metabolic and cognitive responses in male and female mice on the same protocol. Every human trial has been small and none was powered to look. This is a prespecified subgroup analysis waiting for a trial large enough to carry it.
Nobody has established the interval. Protocols use days on and weeks off, and the length of the off period is chosen by analogy rather than by measurement, because nobody has tracked how fast the senescent population rebuilds in a person. A repeat-biopsy or circulating-biomarker time course after one course would set the interval empirically instead of by convention.
Nobody has quantified the quercetin. Quercetin bioavailability varies several-fold between formulations and is notoriously poor for the aglycone. The trials used a specified preparation at 1250 mg Justice 2019; a person buying a supermarket capsule may be taking a small fraction of that exposure. Nobody has compared plasma quercetin across the products people actually use, and without that number the dose on any bottle is a weight, not a dose.
Dasatinib + Quercetin — its own safety story, not its class's
The class block above is written for longevity compounds. This one contains a prescription oncology drug, and that is the whole safety story.
Dasatinib is not a supplement. It is a licensed tyrosine kinase inhibitor whose label carries myelosuppression, fluid retention including pleural effusion, QT prolongation and bleeding risk. Those are label warnings from continuous oncology dosing; the senolytic schedule is three days on, weeks off, and the exposure is far lower. Lower is not the same as absent, and the trials themselves reported adverse events in most participants Justice 2019.
The interaction that catches people is CYP3A4. Dasatinib is a CYP3A4 substrate, so strong inhibitors raise its exposure and inducers lower it. Grapefruit, ketoconazole and several common antibiotics sit on that list, and so do supplements. Quercetin itself has reported effects on drug-metabolizing enzymes and transporters — meaning the two halves of this combination may not be pharmacokinetically independent, which no protocol accounts for. Flagged as a mechanistic expectation from established enzymology, not as a measured interaction in this combination.
Dasatinib also raises gastric pH requirements for other drugs and is itself absorption-sensitive to acid suppression. Anyone on a proton pump inhibitor is taking a different exposure from the trial participants, in the direction of less.
The conceptual risk is the one worth ending on. Senescent cells are not simply debris. They are required for normal wound healing and they limit fibrosis in the short term, and a senolytic taken around surgery or a significant injury removes a function the body is actively using. No one has studied that, and the timing advice that follows from it — do not run a course around an operation or a serious injury — is reasoning from mechanism rather than from a trial.
Sources read for this page
- Zhu Y, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015 · PMID 25754370
- Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine 2019 · PMID 30616998
- Zhu Y, et al. Orally-active, clinically-translatable senolytics restore alpha-Klotho in mice and humans. EBioMedicine 2022 · PMID 35292270
- Zhu X, et al. Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway. International Journal of Molecular Medicine 2024 · PMID 38240118
- Fang Y, et al. Sexual dimorphic metabolic and cognitive responses of C57BL/6 mice to Fisetin or Dasatinib and quercetin cocktail oral treatment. GeroScience 2023 · PMID 37296266
- Wissler Gerdes EO, et al. Strategies for late phase preclinical and early clinical trials of senolytics. Mechanisms of Ageing and Development 2021 · PMID 34699859
Dasatinib + Quercetin — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- Two unrelated molecules doing one job. Dasatinib is a licensed tyrosine kinase inhibitor — an oncology drug — and quercetin is a dietary flavonoid. Senescent cells survive by leaning on anti-apoptotic pathways; the two agents cover different subsets of those dependencies, which is why the pair is used rather than either alone.
- The predicted harm is therefore split, and it is not split evenly. Dasatinib brings a real chemotherapy toxicity profile; quercetin brings a pharmacokinetic problem. Quercetin inhibits CYP3A4 and P-glycoprotein, and dasatinib is a CYP3A4 substrate — so one half of the combination raises the exposure of the other. That is arithmetic about the pair, not an invented interaction.
- The intermittent schedule is the most important thing on this card. Senescent cells do not re-accumulate within hours, so the senolytic model is hit-and-run: a short exposure, then weeks off. Nearly every serious labeled dasatinib toxicity — effusions, cytopenias, pulmonary arterial hypertension — was characterized under continuous daily dosing in leukemia over months and years. A short exposure is a genuinely different exposure. That is an argument for lower risk, not evidence of it.
What has actually been reported
- We are not guessing about dasatinib. Its own label carries these as Warnings and Precautions, not as rare case reports: myelosuppression, bleeding-related events, fluid retention including pleural and pericardial effusion, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, hepatotoxicity and embryo-fetal toxicity. Diarrhea, headache, rash, breathlessness, fatigue, nausea and musculoskeletal pain are the common ones.
- The label's pharmacology travels with the molecule even when the purpose changes: proton pump inhibitors and H2 blockers are not to be taken with it — absorption is pH-dependent and they blunt it — and strong CYP3A4 inhibitors are to be avoided.
- Human senolytic experience is early and small. Open-label and small randomized pilot studies exist in idiopathic pulmonary fibrosis and in diabetic kidney disease, and they were designed to test feasibility, tolerability and whether senescent-cell burden actually falls. They are why the field is taken seriously. They are not a safety database and they were not built to be one.
- Quercetin at dietary and supplement intakes is well tolerated. The concern with it here is the interaction, not the flavonoid.
How to reduce the risk
Same mechanism as the prediction.
- Treat the dasatinib half as what it is — a prescription oncology drug — and have a clinician who can see your full medicine list. Everything else on this card is detail next to that.
- Do not run it continuously. The entire safety argument for the senolytic use rests on short, widely spaced exposures. Daily dosing converts it back into the regimen those label warnings describe.
- Sort the acid suppression out first: on a PPI or H2 blocker it is either interacting or not being absorbed, and neither is the experiment you meant to run.
- New breathlessness, ankle swelling, unusual bruising or bleeding after a course is a reason to be seen, not a reason to wait and see how the next one goes.
What it does to your bloodwork
A fact about the assay.
- Full blood count. Myelosuppression is the most common serious labeled effect and low counts produce no symptom until they are well advanced.
- ALT/AST, because hepatotoxicity is on the label.
- An ECG if there is any QT question, and a clinician who can see your whole medicine list before the first course rather than after it.
- No marker tells you a senolytic worked. The senescence assays used in the trials are research tools; there is nothing you can order that answers the question.
What it overlaps with
- Anything that raises dasatinib exposure: quercetin itself, grapefruit, azole antifungals, clarithromycin. Anything that lowers it: rifampicin, St John's wort, and acid suppression.
- Antiplatelets and anticoagulants add to the labeled bleeding signal. Other QT-prolonging drugs add to that one.
- Stacking it with another senolytic is two versions of the same intent aimed at the same cells, on a schedule established for neither.
Don't run this if
- Pregnancy, breastfeeding or trying to conceive — embryo-fetal toxicity is on the dasatinib label.
- On an anticoagulant or antiplatelet, or with any bleeding disorder, without a clinician in the loop. Bleeding events are a labeled effect.
- Known QT prolongation, or on other QT-prolonging medicines.
- Existing pleural or pericardial effusion, pulmonary hypertension, or poorly controlled heart failure.
- On a proton pump inhibitor or H2 blocker, or on a strong CYP3A4 inhibitor, until that has been sorted out.
The honest unknown
- Whether clearing senescent cells does anything for a healthy human over years. The animal work is genuinely striking, the human trials so far measure feasibility and target engagement, and there is no outcome trial. Unproven is not ineffective — but an oncology drug taken on an unestablished schedule for an unestablished benefit is a risk-benefit judgement, not a supplement decision.
- The right interval is not established. 'Intermittent' is a hypothesis about how quickly senescent cells return in a human, and nobody has measured that.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Dasatinib + Quercetin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Dasatinib + Quercetin moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Dasatinib + Quercetin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Dasatinib + Quercetin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Dasatinib + Quercetin — frequently asked questions
What is Dasatinib + Quercetin?
Dasatinib + Quercetin (D+Q senolytic combination) is a longevity & bioregulators research compound. Dasatinib is a tyrosine kinase inhibitor and quercetin a flavonoid; together they push senescent cells past the apoptotic threshold those cells normally resist. Because senescent cells are cleared and don't return immediately, the dosing is intermittent rather than continuous — a genuinely different pharmacological model.
Is the full Dasatinib + Quercetin protocol on this page?
The reported research dose is on this page, along with how Dasatinib + Quercetin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Dasatinib + Quercetin?
Dasatinib + Quercetin has an approximate half-life of Dasatinib ~3-5 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Dasatinib + Quercetin?
Current evidence level: Early human pilot trials; strong rodent data. Dasatinib + Quercetin is offered for research purposes only and is not an approved medicine.
What Dasatinib + Quercetin is used for
Dasatinib + Quercetin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.